Tyers Asset Management LLC Buys 1,424 Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)

Tyers Asset Management LLC increased its stake in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 32.2% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,840 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,424 shares during the quarter. Tyers Asset Management LLC’s holdings in AMAG Pharmaceuticals were worth $58,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Texas Permanent School Fund increased its stake in shares of AMAG Pharmaceuticals by 4.3% in the 1st quarter. Texas Permanent School Fund now owns 23,570 shares of the specialty pharmaceutical company’s stock valued at $304,000 after acquiring an additional 970 shares in the last quarter. NumerixS Investment Technologies Inc grew its position in AMAG Pharmaceuticals by 17.8% in the 1st quarter. NumerixS Investment Technologies Inc now owns 7,166 shares of the specialty pharmaceutical company’s stock valued at $90,000 after purchasing an additional 1,083 shares during the period. Rhumbline Advisers grew its position in AMAG Pharmaceuticals by 1.1% in the 1st quarter. Rhumbline Advisers now owns 103,866 shares of the specialty pharmaceutical company’s stock valued at $1,338,000 after purchasing an additional 1,125 shares during the period. Swiss National Bank grew its position in AMAG Pharmaceuticals by 2.4% in the 2nd quarter. Swiss National Bank now owns 64,457 shares of the specialty pharmaceutical company’s stock valued at $644,000 after purchasing an additional 1,500 shares during the period. Finally, Riverhead Capital Management LLC grew its position in AMAG Pharmaceuticals by 30.1% in the 2nd quarter. Riverhead Capital Management LLC now owns 6,483 shares of the specialty pharmaceutical company’s stock valued at $65,000 after purchasing an additional 1,500 shares during the period.

AMAG traded down $0.50 during mid-day trading on Friday, reaching $11.79. 876,450 shares of the stock were exchanged, compared to its average volume of 955,980. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.50 and a current ratio of 1.60. The stock has a market capitalization of $415.00 million, a PE ratio of -3.04 and a beta of 0.24. The company has a 50 day moving average price of $10.36 and a two-hundred day moving average price of $10.94. AMAG Pharmaceuticals, Inc. has a 1 year low of $6.81 and a 1 year high of $23.77.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Wednesday, August 7th. The specialty pharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.66) by ($0.62). The firm had revenue of $78.00 million for the quarter, compared to analysts’ expectations of $90.72 million. AMAG Pharmaceuticals had a negative return on equity of 31.31% and a negative net margin of 64.33%. AMAG Pharmaceuticals’s revenue was down 46.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.75) earnings per share. Sell-side analysts expect that AMAG Pharmaceuticals, Inc. will post -3.03 EPS for the current fiscal year.

AMAG has been the subject of several research reports. BidaskClub raised shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 31st. Cowen reissued a “hold” rating and issued a $13.00 price target on shares of AMAG Pharmaceuticals in a research report on Monday, June 24th. Barclays initiated coverage on shares of AMAG Pharmaceuticals in a research report on Tuesday, June 11th. They issued an “overweight” rating and a $19.00 price target for the company. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $9.25 price target for the company in a research report on Thursday, June 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of AMAG Pharmaceuticals in a research report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $15.53.

In other news, major shareholder Camber Capital Management Lp acquired 385,000 shares of the business’s stock in a transaction on Friday, August 9th. The shares were purchased at an average cost of $7.87 per share, with a total value of $3,029,950.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Armistice Capital, Llc acquired 44,000 shares of the business’s stock in a transaction on Thursday, June 27th. The shares were purchased at an average cost of $9.52 per share, for a total transaction of $418,880.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 948,016 shares of company stock worth $7,576,977 over the last ninety days. Insiders own 4.90% of the company’s stock.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Read More: Google Finance

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.